This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chen, C.-L. Articles by Ngan, H. Y. S. Search for Related Content PubMed PubMed Citation Articles by Chen, C.-L. Articles by Ngan, H. Y. S.

Loss of Imprinting of the IGF-II and H19 Genes in Epithelial Ovarian Cancer¹

Department of Obstetrics and Gynecology, The University of Hong Kong, Hong Kong, S.A.R., China

To establish a possible role of genomic imprinting in the carcinogenesis of epithelial ovarian cancer, we determined the imprinting status of both IGF-II and H19 genes in 43 ovarian cancers, 7 low malignant potential ovarian tumors, and their matched normal tissues. In ovarian cancer, loss of heterozygosity (LOH) of IGF-II, H19 RsaI, and H19 AluI was found in 4 of 24 (16.7%), 3 of 20 (15%), and 1 of 16 (6.3%) samples, respectively. All patients with tumor specimens exhibiting LOH are of advanced clinical stages. Loss of imprinting (LOI) was found in 5 of 20 (25%) for IGF-II and in 4 of 17 (23.5%) and 1 of 15 (6.7%) for the RsaI and AluI sites of H19 gene with no LOH. However, no LOH was found in low malignant potential tumors, and only one of them showed LOI in H19 AluI site. Overexpression of IGF-II was demonstrated in all five LOI samples with normal expression of H19. Three of the five tumor specimens exhibiting LOI were transcribed from P1 promoter, whereas the remaining two were from the P3 promoter. These results suggested that LOH of both IGF-II and H19 genes was associated with advanced ovarian cancer. LOI of IGF-II and H19 genes may be involved in the development of ovarian cancer. Transcription of IGF-II from the P1 promoter may account for the biallelic expression of the IGF-II gene.

This article has been cited by other articles:

				Q.-s. Ji, M. J. Mulvihill, M. Rosenfeld-Franklin, A. Cooke, L. Feng, G. Mak, M. O'Connor, Y. Yao, C. Pirritt, E. Buck, et al. A novel, potent, and selective insulin-like growth factor-I receptor kinase inhibitor blocks insulin-like growth factor-I receptor signaling in vitro and inhibits insulin-like growth factor-I receptor dependent tumor growth in vivo Mol. Cancer Ther., August 1, 2007; 6(8): 2158 - 2167. [Abstract] [Full Text] [PDF]

				L. Lu, D. Katsaros, A. Wiley, I. A. Rigault de la Longrais, H. A. Risch, M. Puopolo, and H. Yu The Relationship of Insulin-Like Growth Factor-II, Insulin-Like Growth Factor Binding Protein-3, and Estrogen Receptor-{alpha} Expression to Disease Progression in Epithelial Ovarian Cancer Clin. Cancer Res., February 15, 2006; 12(4): 1208 - 1214. [Abstract] [Full Text] [PDF]

				S. Lottin, E. Adriaenssens, T. Dupressoir, N. Berteaux, C. Montpellier, J. Coll, T. Dugimont, and J. J. Curgy Overexpression of an ectopic H19 gene enhances the tumorigenic properties of breast cancer cells Carcinogenesis, November 1, 2002; 23(11): 1885 - 1895. [Abstract] [Full Text] [PDF]

				G. P. Sawiris, C. A. Sherman-Baust, K. G. Becker, C. Cheadle, D. Teichberg, and P. J. Morin Development of a Highly Specialized cDNA Array for the Study and Diagnosis of Epithelial Ovarian Cancer Cancer Res., May 1, 2002; 62(10): 2923 - 2928. [Abstract] [Full Text] [PDF]

				C.-L. Chen, S.-M. Ip, D. Cheng, L.-C. Wong, and H. Y. S. Ngan p73 Gene Expression in Ovarian Cancer Tissues and Cell Lines Clin. Cancer Res., October 1, 2000; 6(10): 3910 - 3915. [Abstract] [Full Text]